A new study performed single-cell RNA-sequencing on the nephrectomy specimen of a previously untreated patient with RMC. The results suggest that RMC may originate from the thick ascending limb of the Loop of Henle within the renal medulla. Interestingly, the patient carried a likely pathogenic TP53 germ line allele that was somatically lost in the tumor, suggesting that this germline mutation may have conferred a selective disadvantage to RMC tumor cells and was thus negatively selected. Heterogeneous expression of CD70 was noted in a subpopulation of RMC cells. CD70 is a potential therapeutic target for renal cell carcinomas. Lastly, there was evidence of upregulation of the cystine-mTORC-GPX4 signaling axis that may protect RMC cells against ferroptosis.